Carbon constraints, as well as the growing hazard of greenhouse gas emissions, have accelerated research into all possible renewable energy and fuel sources. Microbial electrolysis cells (MECs), a novel technology able to convert soluble organic matter into energy such as hydrogen gas, represent the most recent breakthrough. While research into energy recovery from wastewater using microbial electrolysis cells is fascinating and a carbon-neutral technology that is still mostly limited to lab-scale applications, much more work on improving the function of microbial electrolysis cells would be required to expand their use in many of these applications. The present limiting issues for effective scaling up of the manufacturing process include the high manufacturing costs of microbial electrolysis cells, their high internal resistance and methanogenesis, and membrane/cathode biofouling. This paper examines the evolution of microbial electrolysis cell technology in terms of hydrogen yield, operational aspects that impact total hydrogen output in optimization studies, and important information on the efficiency of the processes. Moreover, life-cycle assessment of MEC technology in comparison to other technologies has been discussed. According to the results, MEC is at technology readiness level (TRL) 5, which means that it is ready for industrial development, and, according to the techno-economics, it may be commercialized soon due to its carbon-neutral qualities.

Pancreatic cancer is a prevalent lethal gastrointestinal cancer that generally does not show any symptoms until it reaches advanced stages, resulting in a high mortality rate. People at high risk, such as those with a family history or chronic pancreatitis, do not have a universally accepted screening protocol. Chemotherapy and radiotherapy demonstrate limited effectiveness in the management of pancreatic cancer, emphasizing the urgent need for innovative therapeutic strategies. Recent studies indicated that the complex interaction among pancreatic cancer cells within the dynamic microenvironment, comprising the extracellular matrix, cancer-associated cells, and diverse immune cells, intricately regulates the biological characteristics of the disease. Additionally, mounting evidence suggests that EVs play a crucial role as mediators in intercellular communication by the transportation of different biomolecules, such as miRNA, proteins, DNA, mRNA, and lipids, between heterogeneous cell subpopulations. This communication mediated by EVs significantly impacts multiple aspects of pancreatic cancer pathogenesis, including proliferation, angiogenesis, metastasis, and resistance to therapy. In this review, we delve into the pivotal role of EV-associated miRNAs in the progression, metastasis, and development of drug resistance in pancreatic cancer as well as their therapeutic potential as biomarkers and drug-delivery mechanisms for the management of pancreatic cancer.